MTMaciej Trojanowski

Maciej Trojanowski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maciej Trojanowski has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mapping population-based cancer registries in Europe: coverage, data availability, and capacity for real-world data generation

    by V. Zadnik, A. Duratović Konjević, M. Jurtela, K. Lokar, N. Bric, T. Zagar, D. Petrova, M.J. Bento, Chirlaque, D. Coza, et al.

  • Open Access

    Changing Burden of Haematolymphoid Tumours in AYA in Poland: Organizational Challenges for the Healthcare System (Current Status and Future Perspectives)

    by Lukasz Taraszkiewicz, Patryk Włodarczyk, Michał Nocek, Maciej Trojanowski, Patrycja Filipek, Urszula Wojciechowska, Joanna A. Didkowska

    Background/Objectives: Hematological malignancies (HMs) are an important component of the cancer burden in adolescents and young adults (AYA, 15–39 years), requiring long-term specialized care. In Poland, recent healthcare reforms under the National Oncology Network (KSO) have not formally included haemato-oncology or AYA-specific needs. Methods: A population-based study was conducted using data from the Polish National Cancer Registry. AYAs diagnosed with HM between 2000 and 2022 were included. Descriptive analyses and projections were based on cases diagnosed between 2000 and 2022, whereas age-specific incidence trend analyses were restricted to the 2015–2022 period. Tumours were classified according to the HAEMCARE framework. Age-standardized incidence rates (ASIRs), annual percentage changes (APCs), and short-term projections through 2028 were estimated using generalized linear models. Additionally, data from the National Health Fund (NFZ) were analyzed to assess the geographical distribution of reimbursed drug programmes dedicated to selected HMs. Results: A total of approximately 23,000 AYA patients diagnosed with HMs were identified. Hodgkin lymphomas (HL) were the predominant tumour type across all age groups, while lymphoblastic leukemia/lymphoma was most common among younger AYAs and diffuse large B-cell lymphoma (DLBCL) increased in relative importance with age. Between 2015 and 2022, ASIRs remained stable only in two age groups (20–24 and 25–29), whereas statistically significant increases were observed among individuals aged 15–19, 30–34 and 35–39 years. Despite largely stable incidence patterns, projections indicated a growing absolute number of cases for DLBCL and follicular lymphomas. Analysis of NFZ data revealed substantial regional variation in the availability of reimbursed drug programmes, with up to six-fold differences in facility density between voivodships. Conclusions: HM epidemiology among AYAs in Poland is characterized by increasing incidence in selected lymphoma subtypes alongside declining mortality. Incorporating haemato-oncology and AYA-specific needs into national cancer planning frameworks should therefore be considered essential for future healthcare system preparedness.

  • Open Access

    European expert consensus on cancer recurrence and progression data collection by population based cancer registries

    by Sinéad T. Hawkins, Helen J. Mitchell, Damien Bennett, Luigino Dal Maso, Xavier Farré, Francesco Giusti, Karen Graham, Dyfed Wyn Huws, Jennifer Lai, Georgios Lyratzopoulos, et al.


  • Open Access

    Outcomes of Radiotherapy With or Without Dose Escalation to Lymph Node Metastases Detected by PET PSMA or Conventional Imaging in Node-Positive Prostate Cancer

    by Mateusz Bilski, Federico Mastroleo, Artur J. Chyrek, Łukasz Kuncman, Piotr Lelek, Magdalena Stankiewicz, Alfonso Gomez- Iturriaga, Marcin Miszczyk, Wojciech Burchardt, Adam Kluska, et al.

    Purpose: To evaluate the impact of PSMA PET versus conventional imaging for staging, and the effect of dose escalation (DE) to metastatic lymph nodes in cN1 prostate cancer patients treated with EBRT and ADT. Methods: A retrospective multicenter analysis included 197 propensity score-matched patients (77 staged with PSMA PET, 120 with conventional imaging) treated with EBRT and ADT, with or without DE to lymph node metastases. Matching criteria were T stage, nodal involvement, imaging modality, Gleason score, and ADT duration. Primary endpoint was metastasis-free survival (MFS); secondary endpoints included overall survival (OS), locoregional control (LRC), and toxicity. Results: Median follow-up was 42 months (IQR: 25–59). Median EQD2 (alpha/beta=1.5) to elective nodes was 46 Gy, and to metastatic nodes, 66 Gy (PSMA PET) and 63 Gy (conventional imaging). The 3-year MFS was 80.5% (95% CI: 71.3–90.8%) for PSMA PET and 77.2% (95% CI: 69.5–85.8%) for conventional imaging; 5-year MFS was 59.3% versus 65.8% ( P =0.57). OS at 5 years was 82.2% (PSMA PET) and 77.4% (conventional imaging) ( P =0.72). On multivariable analysis, ISUP grade group 3–5 predicted earlier metastasis (HR: 4.03, 95% CI: 1.61–10.06; P =0.003); higher prostate dose (EQD2 ≥113 Gy) improved MFS (HR: 0.53, 95% CI: 0.30–0.95; P =0.033); long-term ADT (≥24 mo) improved OS (HR: 0.38, 95% CI: 0.19–0.78; P =0.009). No significant difference in toxicity was observed between groups. Conclusions: PSMA PET staging and nodal dose escalation >60 Gy were safe but did not improve MFS, OS, or LRC. ISUP grade group 3–5 and higher prostate dose significantly influenced outcomes.


  • Open Access

    Body Composition and Survival in Locally Advanced Rectal Cancer Patients Treated with Neoadjuvant Radiochemotherapy

    by Piotr Kolenda, Marcin Mardas, Piotr Radomyski, Maciej Trojanowski, Maria Litwiniuk, Wojciech Warchoł, Marta Stelmach-Mardas

    Background: Nutritional status is a recognized determinant of treatment tolerance and clinical outcomes in oncology. This study aimed to assess body composition using computed tomography (CT) and to evaluate its association with progression-free survival (PFS) and overall survival (OS) in patients with locally advanced rectal cancer (LARC) undergoing curative multimodal therapy. Methods: A total of 216 patients with LARC who underwent neoadjuvant chemoradiotherapy (CRT) were retrospectively assessed. Two radiochemotherapy protocols were used: long-course chemoradiotherapy (lcCRT) (radiation therapy administered daily at doses of 1.8 or 2.0 Gy, for a total dose of 50.4–55.8 Gy) with concurrent chemotherapy: either 5-FU with leucovorin or capecitabine and total neoadjuvant chemoradiotherapy (tnCRT)—short-course radiotherapy (5 × 5 Gy) followed by sequential chemotherapy with CAPOX or FOLFOX. Surgery was performed 6.5 weeks after completing CRT. Radiotherapy was delivered using linear accelerators based on the Intensity-Modulated Radiation Therapy technique. CT scans were used to assess nutritional status. Survival analyses were performed. Data on food consumption frequency were collected using the Dietary Habits and Nutrition Beliefs Questionnaire (KomPAN®). Non-Healthy-Diet-Index-14 (nHDI-14) was calculated. Results: Median observation time was 58 months (range 4–118 months). VATI level and OS (HR: 0.4618 95% CI: 0.2194–0.9719, p = 0.0419), as well as SATI and OS (HR: 0.4707 95% CI: 0.2286–0.9693, p = 0.0409) were significantly associated. This association was not significant for PFS (VATI: HR: 0.7084 95% CI: 0.4055–1.2376, p = 0.2259; SATI: HR: 0.6864 95% CI: 0.3932–1.1981, p = 0.1855). SMI and PMI values were not significantly related either PFS (SMI-HR: 0.6728, 95% CI: 0.4031–1.1231, p = 0.1295; PMI-HR: 0.7385, 95% CI: 0.4628–1.1785, p = 0.2036) or OS (SMI-HR: 0.9128, 95% CI: 0.4703–1.7720, p = 0.7876; PMI-HR: 0.6592 95% CI: 0.3684–1.1794, p = 0.1603). No significant association was found between sarcopenia development and PFS (HR: 1.2733 CI: 0.7589–2.1363; p = 0.3602) or OS (HR: 1.1207; CI: 0.5681–2.2107; p = 0.7424). Significant differences between men and women in alcohol intake and nHDI-14 were observed. Conclusions: Low visceral and subcutaneous adipose tissue index were significantly associated with worse OS in patients with LARC undergoing multimodal treatment. The nHDI-14 was negatively correlated with the duration of observation and patients’ age.


  • Open Access

    MUlticentre REtrospective comparison of definitive EBRT with or without HDR BRAchytherapy boost in patients with locally-advanced prostate cancer and regional lymph NOde metastases (MUREBRANO) – A propensity score matched analysis

    by Mateusz Bilski, Piotr Lelek, Magdalena Stankiewicz, Marcin Miszczyk, Wojciech Burchardt, Adam Kluska, Aleksandra Napieralska, Andrzej Kukiełka, Paweł Cisek, Katarzyna Konat-Bąska, et al.


  • Open Access

    Advancing clinical staging in invasive breast carcinoma: the role of contrast-enhanced mammography

    by Piotr Radomyski, Maciej Trojanowski, Karolina Kijewska, Agnieszka Lis, Joanna Pietkiewicz, Krzysztof Matuszewski, Miroslawa Mocydlarz-Adamcewicz, Łukasz Taraszkiewicz, Witold Kycler

    Purpose: This study compares breast carcinoma (BC) clinical tumour staging by contrast-enhanced mammography (CEM), full-field digital mammography (FFDM), and ultrasound (US). Clinical staging is essential for multidisciplinary teams to develop optimal treatment plans and for cancer registries to generate accurate analyses of cancer epide­miology.Material and methods: Data on tumour size and the presence of multiplicity were extracted from radiology reports. Primary tumour staging (cT category) was established for each imaging modality. Enrolled cases (n = 78, adult females) had FFDM and US performed up to a month prior to CEM. Fisher’s exact test was used to examine the relationship between cT stage determination and diagnostic methods.Results: Tumour size was largest in CEM (median 47 mm), followed by FFDM (median 33 mm), and smallest in US (median 23 mm). There were statistically significant differences in the distribution of cT categories between the 3 imaging modalities, with cT2 and cT1 being most common in US (46% and 41%, respectively) and FFDM (53% and 19%, respectively). Staging by CEM followed a different pattern, with cT2 and cT3 being most common (both 38%). The multiplicity rate was equal for CEM and US (42%), with fewer cases in FFDM (13%).Conclusions: The tumour size measured by CEM is greater compared to measurements obtained through US and FFDM. Given the strong correlation between CEM and histopathology reported in the literature, CEM enhances the accuracy of local tumour staging in BC, thereby minimising the risk of understaging.


  • Advancing cancer data collection: ICD-11 implementation in European oncology and cancer registries

    by Maciej Trojanowski, Irmina Maria Michalek, Anna Kubiak, Łukasz Taraszkiewicz, Witold Kycler


  • Open Access

    The impact of the COVID-19 pandemic on incidence gap in screen-detectable cancers: a cohort study in Greater Poland, Poland

    by Maciej Trojanowski, Piotr Radomyski, Witold Kycler, Irmina Maria Michalek

    Background: The global COVID-19 pandemic has had a significant impact on healthcare systems. This study aimed to assess the incidence gap in screening-detectable cancers in the Greater Poland (Poland) in 2020. Materials and methods: Data on breast, cervix uteri, and colorectal cancer cases diagnosed from 2010 to 2020 were obtained from the regional cancer registry. Standardized incidence ratios (SIR) and incidence rate differences (IRD) were calculated to estimate the change in incident cancer cases during the pandemic. The number of observed cases was extracted from the registry database. Simple linear regression analysis was used to predict the expected number of incident cancer cases in 2020 and the age-standardized incidence rate based on registry data from the preceding ten years (2010–2019). Results: In 2020, the registered number of incident female breast cancer cases decreased by 12% [SIR 0.88, 95% confidence interval (CI): 0.88–0.92, observed: 1,848, expected: 2,101], resulting in an IRD of –6.3 per 100 K. The number of registered cervical cancers decreased by 15% (SIR 0.85, 95% CI: 0.73–0.98, observed: 181, expected: 213), with an IRD of –0.8 per 100 K. For colorectal cancer, there was a 16% decrease in new cases among females (SIR 0.84, 95% CI: 0.78–0.90) and a 15% decrease among males (SIR 0.85, 95% CI: 0.80–0.91), resulting in IRDs of –3.04 and –5.29 per 100K, respectively. Conclusions: The COVID-19 pandemic led to a significant, 15% decrease in newly diagnosed screening-detectable cancer cases in 2020. Further studies are needed to investigate the impact of delayed cancer diagnoses on stage at diagnosis and survival rates. Keywords: cancer cancer diagnosis COVID-19 incidence population-based cancer registry cancer screening